Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

Share Price is delayed by 15 minutes
Get Live Data
113.00    1.50 (1.35%)
Bid:
112.00
Ask:
114.00
Spread: 2.00 (1.786%)
Market Cap: £67.98m
IGP Live PriceLast checked at - London Stock Exchange

Intraday Intercede Share Chart

Trading Update

7 Oct 2009 07:00

RNS Number : 3501A
Intercede Group PLC
07 October 2009
 



7 OCTOBER 2009

INTERCEDE GROUP plc

("Intercede" or "the Company")

Trading Update

Intercede, a leading producer of Identity and Credential Management Systems (IDCMS) software, today announces excellent progress in the six months ended 30 September 2009.

Sales for the first half of the current financial year are more than 40% higher than for the comparable period last year. The Directors are also pleased to report that the Company has strongly increased its operating profit before exceptional items during the period.

The growth in sales is especially encouraging, because it is based both on existing customers expanding deployments installed in earlier periods and on new licence sales into new markets for actual end-customer projects. As a result, we are now experiencing a return on the investment made in development and sales efforts in previous years. Our expansion into new sectors and territories is also producing a fresh and immediate stream of revenue. This is evidence of the ongoing strength and viability of Intercede's business model and of a strategy that is being successfully executed. 

Key achievements during the period include:

Maintaining and expanding existing major projects for Lockheed MartinUK Government, US Federal Government, NHS and others. 

Winning new contracts to supply MyID to customers in AustraliaAustriaCzech RepublicRomaniaSlovakiaSwitzerland and the US.

Deploying MyID systems at a major security printing and smart card manufacturer, at a major Scandinavian bank and within a European government agency.

Adding the US Social Security Administration to Intercede's Federal HSPD-12 customer list. 

Further details will be provided when Intercede announces its Interim Results for the six months ended 30 September 2009, which is expected to take place in December 2009.

The reported period includes exceptional costs for defending a previously reported patent infringement case in the US filed by ActivIdentity Corporation. Intercede's answer and counterclaims deny that its products infringe ActivIdentity's patent and allege further that this patent is invalid and unenforceable. In addition, Intercede has filed counterclaims against ActivIdentity, including alleging violations of US antitrust law. The court recently rejected ActivIdentity's challenge to Intercede's antitrust claims and one basis for a declaration of unenforceability. While the court dismissed other counterclaims alleging fraudunfair competition, and an additional basis for a declaration of unenforceability, it gave Intercede the right to re-plead those claims with more factual detail. Intercede filed its amended counterclaims on 28 September 2009. Intercede intends to pursue its defence and its counterclaims vigorously. 

Costs and cash collections have also been kept under control throughout the period, as evidenced by a half year cash balance of £3,913,00, compared to £3,711,000 at 31 March 2009 and £1,839,000 at 30 September 2008. The cash position as at 30 September 2009 is thus more than double that of a year ago, notwithstanding the legal costs incurred to date in defending the patent infringement case brought by ActivIdentity and in pursuing the Company's counterclaims against ActivIdentity. 

Richard ParrisIntercede's Chairman and Chief Executive, said:

"Our order book indicates that Intercede is on track to continue our planned growth trajectory for this year and beyond. I am delighted that our sales pipeline is stronger than ever and that a number of our existing larger projects are set to exceed expectations in terms of future growth. In particular our entry into the national identity market is proving to be particularly rewarding while our partnerships with Lockheed Martin, Thales and VeriSign are making continuing and growing contributions to operating profit."

About Intercede 

Intercede is the producer of the MyID® Identity and Credential Management System (IDCMS). Intercede's MyID is the only IDCMS software product that enables organizations to easily and securely manage the identities of people and their associated identity credentials within a single, integrated, workflow driven platform. This includes enabling and managing: secure registration, biometric capture, application vetting and approval through to smart card personalization, issuance and management. Intercede's MyID is being used around the world by large corporations, governments and banks to manage millions of identities for employees, citizens and customers. Notable deployments in the US include 10 Federal Agencies, a programme with Lockheed Martin and two major US financial institutions. In Europe and the Middle East, Intercede's MyID is being deployed in support of government identity, health and corporate employee ID security projects.

Intercede and MyID are registered trademarks or trademarks in the UK, US and/or other countries. 

For more information visit http://www.intercede.com.

ENQUIRIES

Intercede Group plc

Tel. +44 (0)1455 558111

Richard Parris, Chairman & Chief Executive

Andrew Walker, Finance Director

FinnCap

Charles Cunningham

Tel. +44 (0)20 7600 1658

Pelham Public Relations

Archie Berens

Tel. +44 (0)20 7337 1509

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TVRFSMFMMSUSEFS
Date   Source Headline
15th Mar 20121:02 pmRNSIssue of Equity
17th Feb 20127:00 amRNSDirector/PDMR Shareholding
16th Feb 20127:00 amRNSTrading Update
12th Dec 20117:00 amRNSUS Expansion
7th Dec 201112:00 pmRNSSales Alliance
1st Dec 20117:00 amRNSInterim Results
14th Nov 20117:00 amRNSNew Partnership
4th Oct 20117:00 amRNSNew Contract Win
21st Sep 20112:55 pmRNSResult of AGM
21st Sep 20117:00 amRNSAGM Statement and Update
17th Aug 20117:00 amRNSDirector/PDMR Share Option Awards
4th Aug 20113:39 pmRNSDirector/PDMR Shareholding
7th Jun 20117:00 amRNSFinal Results
7th Apr 20117:00 amRNSTrading Update
18th Jan 20119:32 amRNSDirector/PDMR Shareholding
6th Dec 20107:00 amRNSTransaction in Own Shares
30th Nov 201011:02 amRNSAdditional Listing and Director dealing
29th Nov 20107:00 amRNSIntercede Group Interim Results
4th Nov 20107:00 amRNSReduction of Share Capital
7th Oct 20107:54 amRNSPositive Trading Update
30th Sep 20107:00 amRNSNew Contract Win
24th Sep 20102:00 pmRNSResult of AGM
22nd Sep 20107:00 amRNSNew Contract Win
7th Sep 20107:00 amRNSPositive Trading Update
15th Jul 20107:00 amRNSLaunch of latest version of MyID PIV
6th Jul 20103:48 pmRNSChange of name of adviser
10th Jun 20107:00 amRNSFinal Results
8th Apr 20107:00 amRNSTrading Update
25th Mar 201012:30 pmRNSSettlement of Patent Dispute
2nd Mar 20107:00 amRNSDirector/PDMR Shareholding
1st Mar 20102:00 pmRNSMajor Subcontract with Thales
1st Feb 20107:00 amRNSNew Aerospace and Defence Contract Win
18th Jan 20104:36 pmRNSDirector/PDMR Shareholding
8th Dec 20097:00 amRNSInterim Results
11th Nov 20097:00 amRNSNew Middle East Contract Win
26th Oct 20097:00 amRNSRelease of latest Version of MyID / New Customers
12th Oct 20097:00 amRNSNational Identity Project in Kuwait
7th Oct 20097:00 amRNSTrading Update
17th Sep 20093:57 pmRNSResult of AGM
29th Jun 20095:11 pmRNSTotal Voting Rights
10th Jun 20097:00 amRNSFinal Results
8th Jun 20095:28 pmRNSDirector/PDMR Shareholding
1st Jun 20097:00 amRNSConversion of Loan Notes
14th May 20097:00 amRNSNew Contract with European Bank
30th Apr 20097:00 amRNSNew European Government Contract
2nd Apr 20097:00 amRNSTrading Update
1st Apr 20097:00 amRNSChange of Adviser
31st Mar 20097:00 amRNSTotal Voting Rights
30th Mar 20097:00 amRNSMaritime Credentialing Program Update
10th Mar 200910:21 amRNSAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.